In this blog post, 3L Staffer Jordan Gilliam writes about the potential impact of the Horseracing Integrity Act on the industry.
Blog by: Matthew Pakkala
In this blog, 3L staffer Matthew Pakkala discusses the ongoing crisis facing the Florida manatees. He briefly introduces the main threat—algae blooms—and details the situation unfolding in the Indian River Lagoon. Pakkala advocates for the Florida manatee to be reclassified as "endangered" under the Endangered Species Act of 1973.
Blog By: Christian T. Deeter
In his blog, 3L Staffer Christian Deeter argues that the Fifth Circuit should hold the Horseracing Integrity and Safety Act (HISA) constitutional because it does not violate the non-delegation and anti-commandeering doctrines. The amended version of HISA adequately reformed the Authority, making it sufficiently subordinate to the Federal Trade Commission (FTC). Deeter supports his opinion with an analysis of the Fifth and Sixth Circuit’s recent rulings.
Blog By: Jose Herrera
In this blog, 3L Staffer Jose Herrera examines the extensive consequences of the booming avocado industry in Michoacán, Mexico. Herrera highlights environmental and social concerns that result from deforestation and corruption and advocates for regulatory reforms to address environmental degradation and safeguard community well-being.
Blog By: Sydney LaRue
The cruise ship industry has a history of harming the environment but has recently implemented energy-efficient technology to limit the amount of greenhouse gases and other waste produced by cruise liners. In this blog, 3L Staffer Sydney LaRue argues that these actions are not enough and that increased regulations on cruise ships are the answer to decreasing the harm cruise liners have on the environment.
Blog By: Nathaniel Richey
In this blog, 3L Staffer Nathaniel Richey discusses how the patent system has the potential to hinder innovation in the agricultural industry. Richey argues in favor of a statutory research exemption from infringement of plant utility patents, drawing parallels with the statutory research exemption applicable to pharmaceuticals and medical devices under the Hatch-Waxman Act.
